Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain

Revista Espanola de Quimioterapia

Volumn 20, Issue 1, 2007, Pages 68-76

  Gobernado, M ^a   Valdes L ^b   Alos J I ^c   Garcia Rey C ^b,f   Dal Re R ^b   Garcia de Lomas J ^d,e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e Instituto Valenciano de Microbiologia   (Spain)

^f AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Escherichia coli; Resistance; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFUROXIME AXETIL; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; NITROFURANTOIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CYSTITIS; DRUG USE; ESCHERICHIA COLI; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRESCRIPTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CYSTITIS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; SPAIN; URINARY TRACT INFECTIONS;

EID: 34250833822     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Warren, J.W., Abrutyn, E., Hebel, J.R. et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 745-758.
2. Hooton, T.M., Stamm, W.E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11: 551-581.
3. Hooton, T.M. Practice guidelines for urinary tract infection in the era of managed care. Int J Antimicrob Agents 1999; 11: 241-245.
4. Stamm, W.E., Hooton, T.M. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328-1334.
5. Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med 2002; 113 (Suppl. 1A): 5S-13S.
6. Garau, J., Xercavins, M., Rodríguez-Carballeira, M. et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-2741.
7. Saenz, Y., Zarazaga, M., Brinas, L. et al. Antibiotic resistance in Escherichia coli isolates obtained from animals, foods and humans in Spain. Int J Antimicrob Agents 2001; 18: 353-358.
8. Oteo, J., Lazaro, E., De Abajo, F.J., Baquero, F., Campos, J.; Spanish members of EARSS. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg Infect Dis 2005; 11: 546-553.
9. Naber, K.G., Bergman, B., Bishop, M.C. et al.; Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001; 40: 576-588.
10. Andreu, A., Alós, J.I., Gobernado, M. et al. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: A nationwide surveillance study. Enferm Infecc Microbiol Clin 2005; 23: 4-9.
11. Gupta, K., Sahm, D.F., Mayfield, D., Stamm, W.E. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis 2001; 33: 89-94.
12. Zhanel, G.G., Karlowsky, J.A., Harding, G.K. et al. A Canadian national surveillance study of urinary tract isolates from outpatients: Comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44: 1089-1092.
13. Kahlmeter, G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22 (Suppl. 2): 49-52.
14. Sahm, D.F., Thornsberry, C., Mayfield, D.C. et al. Multidrug-resistant urinary tract isolates of Escherichia coli: Prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001; 45: 1402-1406.
15. Raz, R., Chazan, B., Kennes, Y. et al.; Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34: 1165-1169.
16. Talan, D.A., Stamm, W.E., Hooton, T.M. et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: A randomized trial. JAMA 2000; 283: 1583-1590.
17. Junquera, S., Loza, E., Baquero, F. Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections. Enferm Infecc Microbiol Clin 2005; 23: 197-201.
18. Alós, J.I., Serrano, M.G., Gómez-Garcés, J.L., Perianes, J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect 2005; 11: 199-203.
19. Pérez-Trallero, E., Urbieta, M., Jiménez, D., García-Arenzana, J.M., Cilia, G. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 1993; 12: 349-351.
20. Goettsch, W., Van Pelt, W., Nagelkerke, N. et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000; 46: 223-228.
21. Karlowsky, J.A., Kelly, L.J., Thornsberry, C., Jones, M.E., Sahm, D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540-2545.
22. Zhanel, G.G., Hisanaga, T.L., Laing, N.M. et al.; NAUTICA Group. Antibiotic resistance in outpatient urinary isolates: Final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005; 26: 380-388.
23. Gupta, K., Hooton, T.M., Wobbe, C.L., Stamm, W.E. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int J Antimicrob Agents 1999; 11: 305-308.
24. Gupta, K., Scholes, D., Stamm, W.E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999; 281: 736-738.
25. Carbon, C., Cars, O., Christiansen, K. Moving from recommendation to implementation and audit: Part 1. Current recommendations and programs: A critical commentary. Clin Microbiol Infect 2002; 8 (Suppl. 2): 92-106.
26. Seppala, H., Klaukka, T., Lehtonen, R., Nenonen, E., Huovinen, P. Outpatient use of erythromycin: Link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21: 1378-1385.
27. Granizo, J.J., Aguilar, L., Casal, J. et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-773.
28. Granizo, J.J., Aguilar, L., Casal, J., Dal-Ré, R., Baquero, F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000; 46: 959-964.
29. Seppala, H., Klaukka, T., Vuopio-Varkila, J. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-446.
30. Stephenson, J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA 1996; 275: 175.
31. Kristinsson, K.G. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 1997; 3: 117-123.
32. Goossens, H., Ferech, M., Van der Stichele, R., Elseviers, M.; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-587.
33. Cizman, M., Orazem, A., Krizan-Hergouth, V., Kolman, J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections. J Antimicrob Chemother 2001; 47: 502.
34. Urbanek, K., Kolar, M., Strojil, J. et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: Inpatients and outpatients. Pharmacoepidemiol Drug Saf 2005; 14: 741-745.
35. Bremon, A.R., Ruiz-Tovar, M., Gorricho, B.P., De Torres, P.D., Rodríguez, R.L. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother 2000; 45: 395-400.
36. Bengoa, E.L., Sanz, M.M., De Abajo Iglesias, F.J. Trends in antibiotic consumption in Spain, 1985-2000. Med Clin (Barc) 2002; 118: 561-568.
37. Wise, R., Hart, T., Cars, O. et al. Antimicrobial resistance is a major threat to public health. BMJ 1998; 317: 609-610.